Jernigan continues prominent role on national advisory board for Susan G. Komen

Susan G. Komen Greater Kansas City is proud to continue local representation on the Susan G. Komen Scientific Advisory Board (SAB): Cheryl Jernigan, CPA, FACHE. Jernigan also serves on the Komen Kansas City Board of Directors. Her focus continues to be on patient and research advocacy; clinical trials, clinical data research; big data (BD4BC); and cancer prevention. Jernigan is also a 21-year breast cancer survivor and one of the leading team captains (based on dollars raised) for the local Race for the Cure.

Cheryl Jernigan - Mission Advisors Roster FY18_Page_1She was previously CEO of the Kansas City Area Hospital Association, and has over 20 years of experience in health policy, advocacy and community/national leadership on behalf of hospitals. She is Chair of the Breast Cancer Prevention Center’s Advocate Advisory Board for The University of Kansas Medical Center and The University of Kansas Hospital, and she is the Lead Advocate of Patient & Investigator Voices Organizing Together (PIVOT), a new University of Kansas Cancer Center initiative. Jernigan is a founding and current board member and Chair of the Strategic Mission Committee of the Greater Kansas City Komen Affiliate, and a member of the Steering Committee of Komen’s Advocates In Science program. An active research advocate, Jernigan is a member of many clinical trial initiatives, including the National Cancer Institute’s Central Institutional Review Board for Adult Late Phase Clinical Trials. Jernigan is also one of the experts involved with Komen’s big data initiative.

In addition to Jernigan, the Greater Kansas City community is fortunate to be the home of Komen Scholar Danny Welch, PHDProfessor and Chair, Adjunct faculty of Department of Molecular & Integrative Physiology. Welch, a researcher at the University of Kansas Medical Center, focuses on laboratory and translational research; metastasis; as well as mitochondrial genetics and mutations that lead to breast cancer. Welch is also a multi-year recipient of Komen Promise Grant dollars for his work on metastasis.

Click here to see a full list of the 2017-2018 Komen Mission Advisors..

Komen’s Mission Advisors

Komen’s Mission Advisors are the best and brightest researchers, clinicians, advocates & other experts who guide/help implement our mission programs.

Thanks to their efforts, we’re driving discovery, affecting change & accelerating progress in the fight against breast cancer.

The Scientific Advisory Board are providing strategic guidance for our research & scientific programs. They play a key role in prioritizing our global research investment. The SAB is led by the chief scientific advisors & acts as the executive committee of the Komen Scholars.

The Komen Scholars (KS) are an international group that has a wide range of expertise (clinical & laboratory research, surgery, pathology, prevention, disparities, radiation   oncology & other specialties).

They contribute in many ways to Komen’s mission programs & other activities/events with primary responsibility for leading & reviewing during Komen’s scientific peer review process. KS serve as ambassadors & experts in our communities and across the Affiliate Network.

Several of the KS are Advocates in Science who ensure that the unique perspectives of those affected by breast cancer are fully integrated in our decisions at every step of the research process.

Komen announces nearly $33 million in new research funding to support bold goal

SUSAN G. KOMEN® ANNOUNCES NEARLY $33 MILLION IN NEW RESEARCH FUNDING TO SUPPORT BOLD GOAL OF CUTTING BREAST CANCER MORTALITY BY 50 PERCENT

 Kansas Researchers Receive $650,000 in Research Funding

DALLAS – September 19, 2016 – Building on its bold goal to reduce current breast cancer deaths by 50 percent in the U.S. over the next decade, Susan G. Komen, the world’s leading breast cancer organization, today announced $32.7 million in new research grants for 2016. Awarded across 23 states and 7 countries, the projects span the entire continuum of breast cancer research, including research into metastatic disease, novel treatments for aggressive types of breast cancer, new technologies and health equity – areas that will make a significant impact in achieving the 50 percent goal.

The grants include $650,000 in new funding for research at the University of Kansas Medical Center Research Institute in Kansas, bringing Komen’s total research investment in Kansas to $10,191,251 since 1982.

“For nearly 35 years our organization has been a leader in the fight to end breast cancer, changing how people think about, talk about and treat this disease. Now, with a sharpened focus on our organization’s new strategic direction, we are delighted to announce new research funding that will play a significant role in making our bold goal a reality,” said Komen President and CEO Judy Salerno, M.D., M.S.

“Not only will these grants accelerate our understanding of key areas in breast cancer research, but they include funding for early-career investigators. As federal research dollars become increasingly difficult to secure, these awards give promising young researchers an opportunity to establish their careers, and help ensure breakthrough breast cancer research continues for years to come,” Dr. Salerno added. “Their work is essential to achieving our vision of a world without breast cancer.”

Grants from Komen’s nearly $33 million 2016 research portfolio* – including more than $16 million to early-career investigators – will focus on promising areas in research that have the greatest potential to save lives, including:

  • 38 grants expanding our knowledge of metastatic breast cancer and how to stop it.
  • 15 grants looking into novel treatments for aggressive types of breast cancer (specifically, triple negative, Luminal B and inflammatory breast cancer).
  • 21 grants advancing our ability to detect primary and recurrent breast cancer at its earliest stages.
  • 12 grants identifying the causes of breast cancer disparities and testing ways to overcome barriers to care.

Komen’s Investments in Kansas

Komen’s research program is funded in part by contributions from Komen’s nationwide Network of Affiliates, which direct 25 percent of funds raised locally to Komen’s national research program, while investing the remaining 75 percent into community outreach programs that serve local women and men facing breast cancer.

Since 1994, Komen Kansas City has funded more than $16 million to community programs serving local women and men, while contributing more than $4 million to Komen research.

“We are so grateful for the friends, family and neighbors who fight for the cures alongside us, helping to reduce the number of breast cancer deaths in Kansas and Missouri, both on the ground and through groundbreaking research,” said Carli Good, Executive Director of the Greater Kansas City affiliate.

In Kansas, researchers will receive $650,000.

The University of Kansas Medical Center Research Institute

  • Komen Scholar Danny Welch, Ph.D., will receive $200,000 to study the role of genes that suppress the ability of breast cancer cells to spread to other parts of the body (metastasis). By understanding why and how metastasis happens, new targets can be identified for therapy and guide treatment decisions.
  • Christy Hagan, Ph.D. will receive $450,000 to examine how inflammation fuels hormone-responsive breast cancers. Dr. Hagan will determine if anti-inflammatory drugs should be added as a treatment option with current anti-hormone-based therapies.

These new funds bring Komen’s total research investment to more than $920 million since opening its doors in 1982, the largest of any nonprofit outside the U.S. government. In addition to research, Komen and its nationwide network of Affiliates serve women and men in thousands of communities. To date, more than $2 billion has been invested in community programs that provide education, screening and treatment support.

About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization outside of the federal government, funding more breast cancer research than any other nonprofit while providing real-time help to those facing the disease. Since its founding in 1982, Komen has funded more than $920 million in research and provided more than $2 billion in funding to screening, education, treatment and psychosocial support programs. Komen has worked in more than 60 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social

About Susan G. Komen® Greater Kansas City
Susan G. Komen® Greater Kansas City is working to better the lives of those facing breast cancer in the local community. Through events like the Komen Kansas City Race for the Cure®, Rock the Ribbon and the Pink Promise Conference, Komen KC has invested more than $20 million in community breast health programs throughout 17 Kansas and Missouri counties and has helped contribute to the more than $889 million invested globally in researchVisit komenkansascity.org or call 816.842.0410. Connect with us on social media: facebook.com/komenkansascitytwitter.com/komenkansascity or instagram.com/komenkc.